Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1CNS 1Breast 1

Conditions

Waldenstrom Macroglobulinemia 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Simvastatin × Lymphoid × Clear all
NCT00575965 2015-12-16

Simvastatin in Waldenstrom's Macroglobulinemia

Dana-Farber Cancer Institute

Phase 2 Terminated
18 enrolled 5 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡